Odyssey Therapeutics Inc.
ODTX | NASDAQ
$19.14
-$0.40 (-2.05%)
Nov 2, 2026, 10:38 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Revenue | n/a | n/a |
Cost of Revenue | n/a | n/a |
Gross Profit | n/a | n/a |
Operating Income | -95.25M | -39.78M |
Interest Income | 4.54M | 1.71M |
Pretax Income | -91M | -38.2M |
Net Income | -91.05M | -38.26M |
Selling & General & Admin | 17.86M | 7.35M |
Research & Development | 68.55M | 32.32M |
Other Expenses | 8.84M | 109K |
Operating Expenses | 95.25M | 39.78M |
Interest Expense | 30K | 10K |
Selling & Marketing Expenses | n/a | n/a |
Cost & Expenses | 95.25M | 39.78M |
Income Tax Expense | 55K | 63K |
Shares Outstanding (Basic) | 30.28M | 47.17M |
Shares Outstanding (Diluted) | 30.28M | 47.17M |
EPS (Basic) | -2.55 | -0.81 |
EPS (Diluted) | -2.55 | -0.81 |
EBITDA | -88.75M | -37.02M |
EBIT | -90.97M | -38.19M |
Depreciation & Amortization | 2.21M | 1.17M |
Add to Watchlist
Select watchlists to add or remove ODTX